Substrate determinants in the C99 juxtamembrane domains differentially affect γ-secretase cleavage specificity and modulator pharmacology

Journal of Neurochemistry

Volumn 125, Issue 4, 2013, Pages 610-619

  Ousson, Solenne ^a,b   Saric, Arman ^a   Baguet, Aurelie ^a   Losberger, Christophe ^a   Genoud, Stephane ^a   Vilbois, Francis ^a   Permanne, Bruno ^a,b   Hussain, Ishrut ^a   Beher, Dirk ^a,b  

^a MERCK SERONO S A   (Switzerland)

^b EPFL   (Switzerland)

Author keywords

secretase; Alzheimer's disease; amyloid precursor protein; aspartyl protease; cleavage specificity; transmembrane domain

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN 32; AMYLOID BETA PROTEIN 33; AMYLOID BETA PROTEIN 34; AMYLOID BETA PROTEIN 37; AMYLOID BETA PROTEIN 38; AMYLOID BETA PROTEIN 39; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; GLUTAMIC ACID; LEUCINE; LYSINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; JUXTAMEMBRANE DOMAIN; MUTANT; MUTATIONAL ANALYSIS; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN SYNTHESIS; SITE DIRECTED MUTAGENESIS; STRUCTURE ANALYSIS; UPREGULATION; WESTERN BLOTTING; WILD TYPE;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; BINDING SITES; ENZYME ACTIVATION; HEK293 CELLS; HUMANS; LEUCINE; LYSINE; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; SUBSTRATE SPECIFICITY;

EID: 84876797754     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12129     Document Type: Article

References (42)

1. Ahn K., Shelton C. C., Tian Y., Zhang X., Gilchrist M. L., Sisodia S. S., and, Li Y. M., (2010) Activation and intrinsic gamma-secretase activity of presenilin 1. Proc. Natl Acad. Sci. USA 107, 21435-21440.
2. Beher D., Wrigley J. D., Owens A. P., and, Shearman M. S., (2002) Generation of C-terminally truncated amyloid-beta peptides is dependent on gamma-secretase activity. J. Neurochem. 82, 563-575.
3. Beher D., Clarke E. E., Wrigley J. D., Martin A. C., Nadin A., Churcher I., and, Shearman M. S., (2004) Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism. J. Biol. Chem. 279, 43419-43426.
4. Borgegard T., Jureus A., Olsson F., et al,. (2012) First and second generation gamma-secretase modulators (GSMs) modulate amyloid-beta (Abeta) peptide production through different mechanisms. J. Biol. Chem. 287, 11810-11819.
5. De S. B., Annaert W., Cupers P., et al,. (1999) A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 398, 518-522.
6. Dyrks T., Dyrks E., Masters C., and, Beyreuther K., (1992) Membrane inserted APP fragments containing the beta A4 sequence of Alzheimer's disease do not aggregate. FEBS Lett. 309, 20-24.
7. Ebke A., Luebbers T., Fukumori A., Shirotani K., Haass C., Baumann K., and, Steiner H., (2011) Novel gamma-secretase enzyme modulators directly target presenilin protein. J. Biol. Chem. 286, 37181-37186.
8. Edbauer D., Winkler E., Regula J. T., Pesold B., Steiner H., and, Haass C., (2003) Reconstitution of gamma-secretase activity. Nat. Cell Biol. 5, 486-488.
9. Esler W. P., Kimberly W. T., Ostaszewski B. L., Diehl T. S., Moore C. L., Tsai J. Y., Rahmati T., Xia W., Selkoe D. J., and, Wolfe M. S., (2000) Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1. Nat. Cell Biol. 2, 428-434.
10. Francis R., McGrath G., Zhang J., et al,. (2002) aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev. Cell 3, 85-97.
11. Glenner G. G., and, Wong C. W., (1984) Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885-890.
12. Goutte C., Tsunozaki M., Hale V. A., and, Priess J. R., (2002) APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos. Proc. Natl Acad. Sci. USA 99, 775-779.
13. Kimberly W. T., LaVoie M. J., Ostaszewski B. L., Ye W., Wolfe M. S., and, Selkoe D. J., (2003) Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc. Natl Acad. Sci. USA 100, 6382-6387.
14. Kukar T. L., Ladd T. B., Bann M. A., et al,. (2008) Substrate-targeting gamma-secretase modulators. Nature 453, 925-929.
15. Kukar T. L., Ladd T. B., Robertson P., et al,. (2011) Lysine 624 of the amyloid precursor protein (APP) is a critical determinant of amyloid beta peptide length: support for a sequential model of gamma-secretase intramembrane proteolysis and regulation by the amyloid beta precursor protein (APP) juxtamembrane region. J. Biol. Chem. 286, 39804-39812.
16. Li Y. M., Xu M., Lai M. T., et al,. (2000) Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 405, 689-694.
17. Lichtenthaler S. F., Ida N., Multhaup G., Masters C. L., and, Beyreuther K., (1997) Mutations in the transmembrane domain of APP altering gamma-secretase specificity. Biochemistry 36, 15396-15403.
18. Lichtenthaler S. F., Multhaup G., Masters C. L., and, Beyreuther K., (1999a) A novel substrate for analyzing Alzheimer's disease gamma-secretase. FEBS Lett. 453, 288-292.
19. Lichtenthaler S. F., Wang R., Grimm H., Uljon S. N., Masters C. L., and, Beyreuther K., (1999b) Mechanism of the cleavage specificity of Alzheimer's disease gamma-secretase identified by phenylalanine-scanning mutagenesis of the transmembrane domain of the amyloid precursor protein. Proc. Natl Acad. Sci. USA 96, 3053-3058.
20. Lichtenthaler S. F., Beher D., Grimm H. S., Wang R., Shearman M. S., Masters C. L., and, Beyreuther K., (2002) The intramembrane cleavage site of the amyloid precursor protein depends on the length of its transmembrane domain. Proc. Natl Acad. Sci. USA 99, 1365-1370.
21. Lleo A., Berezovska O., Herl L., Raju S., Deng A., Bacskai B. J., Frosch M. P., Irizarry M., and, Hyman B. T., (2004) Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation. Nat. Med. 10, 1065-1066.
22. Masters C. L., Simms G., Weinman N. A., Multhaup G., McDonald B. L., and, Beyreuther K., (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl Acad. Sci. USA 82, 4245-4249.
23. Munter L. M., Voigt P., Harmeier A., Kaden D., Gottschalk K. E., Weise C., Pipkorn R., Schaefer M., Langosch D., and, Multhaup G., (2007) GxxxG motifs within the amyloid precursor protein transmembrane sequence are critical for the etiology of Abeta42. EMBO J. 26, 1702-1712.
24. Murphy M. P., Hickman L. J., Eckman C. B., Uljon S. N., Wang R., and, Golde T. E., (1999) gamma-Secretase, evidence for multiple proteolytic activities and influence of membrane positioning of substrate on generation of amyloid beta peptides of varying length. J. Biol. Chem. 274, 11914-11923.
25. Narlawar R., Baumann K., Czech C., and, Schmidt B., (2007) Conversion of the LXR-agonist TO-901317-from inverse to normal modulation of gamma-secretase by addition of a carboxylic acid and a lipophilic anchor. Bioorg. Med. Chem. Lett. 17, 5428-5431.
26. Ohki Y., Higo T., Uemura K., Shimada N., Osawa S., Berezovska O., Yokoshima S., Fukuyama T., Tomita T., and, Iwatsubo T., (2011) Phenylpiperidine-type gamma-secretase modulators target the transmembrane domain 1 of presenilin 1. EMBO J. 30, 4815-4824.
27. Page R. M., Gutsmiedl A., Fukumori A., Winkler E., Haass C., and, Steiner H., (2010) Beta-amyloid precursor protein mutants respond to gamma-secretase modulators. J. Biol. Chem. 285, 17798-17810.
28. Qi-Takahara Y., Morishima-Kawashima M., Tanimura Y., et al,. (2005) Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase. J. Neurosci. 25, 436-445.
29. Quintero-Monzon O., Martin M. M., Fernandez M. A., Cappello C. A., Krzysiak A. J., Osenkowski P., and, Wolfe M. S., (2011) Dissociation between the processivity and total activity of gamma-secretase: implications for the mechanism of Alzheimer's disease-causing presenilin mutations. Biochemistry 50, 9023-9035.
30. Ren Z., Schenk D., Basi G. S., and, Shapiro I. P., (2007) Amyloid beta-protein precursor juxtamembrane domain regulates specificity of gamma-secretase-dependent cleavages. J. Biol. Chem. 282, 35350-35360.
31. Sagi S. A., Lessard C. B., Winden K. D., Maruyama H., Koo J. C., Weggen S., Kukar T. L., Golde T. E., and, Koo E. H., (2011) Substrate sequence influences gamma-secretase modulator activity, role of the transmembrane domain of the amyloid precursor protein. J. Biol. Chem. 286, 39794-39803.
32. Sato T., Tang T. C., Reubins G., Fei J. Z., Fujimoto T., Kienlen-Campard P., Constantinescu S. N., Octave J. N., Aimoto S., and, Smith S. O., (2009) A helix-to-coil transition at the epsilon-cut site in the transmembrane dimer of the amyloid precursor protein is required for proteolysis. Proc. Natl Acad. Sci. USA 106, 1421-1426.
33. Seiffert D., Bradley J. D., Rominger C. M., et al,. (2000) Presenilin-1 and -2 are molecular targets for gamma-secretase inhibitors. J. Biol. Chem. 275, 34086-34091.
34. Takami M., Nagashima Y., Sano Y., Ishihara S., Morishima-Kawashima M., Funamoto S., and, Ihara Y., (2009) gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J. Neurosci. 29, 13042-13052.
35. Takasugi N., Tomita T., Hayashi I., Tsuruoka M., Niimura M., Takahashi Y., Thinakaran G., and, Iwatsubo T., (2003) The role of presenilin cofactors in the gamma-secretase complex. Nature 422, 438-441.
36. Theuns J., Marjaux E., Vandenbulcke M., Van L. K., Kumar-Singh S., Bormans G., Brouwers N., Van den B., and, M., Vennekens K., Corsmit E., Cruts M., De S. B., Van B. C. and Vandenberghe R., (2006) Alzheimer dementia caused by a novel mutation located in the APP C-terminal intracytosolic fragment. Hum. Mutat. 27, 888-896.
37. Uemura K., Farner K. C., Hashimoto T., Nasser-Ghodsi N., Wolfe M. S., Koo E. H., Hyman B. T., and, Berezovska O., (2010) Substrate docking to gamma-secretase allows access of gamma-secretase modulators to an allosteric site. Nat. Commun. 1, 130.
38. Weggen S., and, Beher D., (2012) Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease. Alzheimers Res. Ther. 4, 9.
39. Wolfe M. S., Xia W., Ostaszewski B. L., Diehl T. S., Kimberly W. T., and, Selkoe D. J., (1999) Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 398, 513-517.
40. Wrigley J. D., Schurov I., Nunn E. J., Martin A. C., Clarke E. E., Ellis S., Bonnert T. P., Shearman M. S., and, Beher D., (2005) Functional overexpression of gamma-secretase reveals protease-independent trafficking functions and a critical role of lipids for protease activity. J. Biol. Chem. 280, 12523-12535.
41. Yu G., Nishimura M., Arawaka S., et al,. (2000) Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. Nature 407, 48-54.
42. Zhang J., Ye W., Wang R., Wolfe M. S., Greenberg B. D., and, Selkoe D. J., (2002) Proteolysis of chimeric beta-amyloid precursor proteins containing the Notch transmembrane domain yields amyloid beta-like peptides. J. Biol. Chem. 277, 15069-15075.